Annals of Surgical Oncology, Vol 5, Issue 2 140-149, Copyright © 1998 by Society of Surgical Oncology

ARTICLES

Association between extent of axillary lymph node dissection and survival in patients with stage I breast cancer

J. A. Sosa, M. Diener-West, Y. Gusev, M. A. Choti, J. R. Lange, W. C. Dooley and M. A. Zeiger
Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

BACKGROUND: The role of axillary lymph node dissection for stage I (T1N0) breast cancer remains controversial because patients can receive adjuvant chemotherapy regardless of their nodal status and because its therapeutic benefit is in question. The purpose of this study was to determine whether extent of axillary dissection in patients with T1N0 disease is associated with survival. METHODS: Data from 464 patients with T1N0 breast cancer who underwent axillary dissection from 1973 to 1994 were examined retrospectively. Kaplan-Meier estimates of overall survival, disease-free survival, and recurrence were calculated for patients according to the number of lymph nodes removed (<10 or > or = 10; <15 or > or = 15), and survival curves compared using the Wilcoxon-Gehan statistic. Cox proportional hazards regression modelling was used to adjust for confounding prognostic variables. RESULTS: Median follow-up time was 6.4 years. Patient groups were similar in age, menopausal status, tumor size, hormonal receptor status, type of surgery, and adjuvant therapy. There was a statistically significant improvement in disease-free survival in the > or = 10 versus <10 nodal groups (P <.01). Five-year estimates of survival were 75.7% and 86.2% for <10 nodes and > or = 10 nodes, respectively; 10-year estimates were 66.1% and 74.3%. There also was a notable improvement in the survival comparison of patients with <15 versus > or = 15 nodes (P < or = .05). These findings were confirmed in the multivariate analysis. CONCLUSIONS: These results may reflect a potential for misclassification of tumor stage among patients who had fewer nodes removed. The data, however, suggest that in patients with Stage I breast cancer, improved survival is associated with a more complete axillary lymph node dissection.

This article has been cited by other articles:

				J. K. Chan, E. G. Munro, M. K. Cheung, A. Husain, N. N. Teng, J. S. Berek, and K. Osann Association of Lymphadenectomy and Survival in Stage I Ovarian Cancer Patients Obstet. Gynecol., January 1, 2007; 109(1): 12 - 19. [Abstract] [Full Text] [PDF]

				I Blancas, J. Garcia-Puche, B Bermejo, E. Hanrahan, C Monteagudo, A Martinez-Agullo, R Rouzier, B. Hennessy, V Valero, and A Lluch Low number of examined lymph nodes in node-negative breast cancer patients is an adverse prognostic factor Ann. Onc., November 1, 2006; 17(11): 1644 - 1649. [Abstract] [Full Text] [PDF]

				A. Fleischmann, G. N. Thalmann, R. Markwalder, and U. E. Studer Extracapsular Extension of Pelvic Lymph Node Metastases From Urothelial Carcinoma of the Bladder Is an Independent Prognostic Factor J. Clin. Oncol., April 1, 2005; 23(10): 2358 - 2365. [Abstract] [Full Text] [PDF]

				J E A Somner, J M J Dixon, and J S J Thomas Node retrieval in axillary lymph node dissections: recommendations for minimum numbers to be confident about node negative status J. Clin. Pathol., August 1, 2004; 57(8): 845 - 848. [Abstract] [Full Text] [PDF]

				Y. Nieto, S. Nawaz, E. J. Shpall, S. I. Bearman, J. Murphy, and R. B. Jones Long-Term Analysis and Prospective Validation of a Prognostic Model for Patients with High-Risk Primary Breast Cancer Receiving High-Dose Chemotherapy Clin. Cancer Res., April 15, 2004; 10(8): 2609 - 2617. [Abstract] [Full Text] [PDF]

				K. J. Van Zee, D.-M. E. Manasseh, J. L. B. Bevilacqua, S. K. Boolbol, J. V. Fey, L. K. Tan, P. I. Borgen, H. S. Cody III, and M. W. Kattan A Nomogram for Predicting the Likelihood of Additional Nodal Metastases in Breast Cancer Patients With a Positive Sentinel Node Biopsy Ann. Surg. Oncol., December 1, 2003; 10(10): 1140 - 1151. [Abstract] [Full Text] [PDF]

				D. N. Krag and R. M. Single Breast Cancer Survival According to Number of Nodes Removed Ann. Surg. Oncol., December 1, 2003; 10(10): 1152 - 1159. [Abstract] [Full Text] [PDF]

				F.C. Wright, J. Walker, C.H.L. Law, and D.R. McCready Outcomes After Localized Axillary Node Recurrence in Breast Cancer Ann. Surg. Oncol., November 1, 2003; 10(9): 1054 - 1058. [Abstract] [Full Text] [PDF]

				T.-C. Chao, M.-F. Chen, C.-S. Wang, Y.-Y. Jan, T.-L. Hwang, and S.-C. Chen Small Invasive Breast Carcinomas in Taiwanese Women Ann. Surg. Oncol., August 1, 2003; 10(7): 740 - 747. [Abstract] [Full Text] [PDF]

				L. Weir, C. Speers, Y. D'yachkova, and I. A. Olivotto Prognostic Significance of the Number of Axillary Lymph Nodes Removed in Patients With Node-Negative Breast Cancer J. Clin. Oncol., April 1, 2002; 20(7): 1793 - 1799. [Abstract] [Full Text] [PDF]

				S Frkovic-Grazio and M Bracko Long term prognostic value of Nottingham histological grade and its components in early (pT1N0M0) breast carcinoma J. Clin. Pathol., February 1, 2002; 55(2): 88 - 92. [Abstract] [Full Text] [PDF]

				S. L. Wong, M. J. Edwards, C. Chao, T. M. Tuttle, R. D. Noyes, C. Woo, P. B. Cerrito, K. M. McMasters, and for the University of Louisville Breast Cancer Sen Predicting the Status of the Nonsentinel Axillary Nodes: A Multicenter Study Arch Surg, May 1, 2001; 136(5): 563 - 568. [Abstract] [Full Text] [PDF]

				R. K. Orr, J. L. Hoehn, and N. F. Col The Learning Curve for Sentinel Node Biopsy in Breast Cancer: Practical Considerations Arch Surg, July 1, 1999; 134(7): 764 - 767. [Abstract] [Full Text] [PDF]

				K. M. McMasters, A. E. Giuliano, M. I. Ross, D. S. Reintgen, K. K. Hunt, D. R. Byrd, V. S. Klimberg, P. W. Whitworth, L. C. Tafra, and M. J. Edwards Sentinel-Lymph-Node Biopsy for Breast Cancer -- Not Yet the Standard of Care N. Engl. J. Med., October 1, 1998; 339(14): 990 - 995. [Full Text]